Andrew Foxley - AstraZeneca-澳门在线赌城娱乐

I serve as Vice President and Franchise Head in Late Oncology R&D at AstraZeneca. In my current role, I lead the cross-functional R&D Franchise for development and launch of two of our key late stage oncology molecules: capivasertib and AZD9833. As part of that I also lead the Global Product Team for capivasertib.

Having spent more than 30 years in a pharmaceutical research setting, my experience in medicines development spans the cardiovascular and oncology therapeutic areas across all phases of drug development. In oncology I have worked on projects studying a range of tumour types including breast, prostate, lung, gastrointestinal, acute myeloid leukaemia and diffuse large B-cell lymphoma.

I joined AstraZeneca Clinical Operations in 2003 and have since held positions in both clinical operations and strategic drug development with increasing levels of responsibilities including development and delivery of a wide range of international drug development programmes. In these roles I have found tremendous value in partnering with external experts and throughout my career, I have organised and chaired corporate and academic advisory boards and served as secretary to several academic steering committees.

Before joining AstraZeneca, I was an Executive Director and Board Member at NCRL, a specialist contract research organisation specialising in the design and delivery of large-scale cardiovascular studies in which I played a leading role in developing the enterprise from a university spin-off company.

Being connected with the external research community is really important to me and I hold a number of honorary positions outside AstraZeneca including chair of the New Medicines and Data Strategic Leadership Group at the Association of the British Pharmaceutical Industry, co-chair of the UK Clinical Pharmacology Skills Alliance, and chair of the UK Clinical Pharmacology Trailblazer Apprenticeship Group.

At AstraZeneca, we are committed to pushing new boundaries in oncology research and helping to speed the delivery of high-quality, targeted medicines to patients. I am passionate about translating scientific research into outcomes that improve the lives of patients.

Andrew Foxley Vice President, Franchise Head, Late Oncology R&D

2019 – 2020

Led the cross-functional global product team for the late-stage development of capivasertib in the role of Project Vice President, Global Medicines Leader at AstraZeneca

2017 – 2019

Worked as Global Transition Director at AstraZeneca in late stage development to support molecules preparing to move from early to late stage development – this included leading capivasertib into late-stage development

2015 – 2017

Served as Head of Clinical Project Management for the Early Oncology Translational Medicine Unit at AstraZeneca

2013 – 2015

Contributed to the establishment of a new early clinical development function and became Senior Director of Scientific Project Management, Early Oncology Clinical Development at AstraZeneca

2007 – 2013

As a Clinical Program Leader at AstraZeneca, led clinical development for numerous early stage molecules from Phase 1 to proof of concept delivering clinical development plans for 6 oncology compounds spanning prostate, breast, lung, ovarian, endometrial, gastric, hepatic and haematological cancers

2005 – 2007

Section Director for a unit of c. 100 staff working in UK Clinical Operations at AstraZeneca

2003 – 2004

Line manager of a team of clinical trial leaders and coordinators working on global R&D studies in respiratory, cardiovascular and inflammatory indications at AstraZeneca

1997 – 2002

Executive company director at Nottingham Clinical Research Limited

2016

Awarded Honorary membership of the faculty of pharmaceutical medicine of the Royal College of Physicians, UK

2013

Awarded Nominated for numerous achievement awards including recipient of an annual Individual Special Recognition Award

Featured publications

Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH, Hall PS, Perren T, Stein RC, Mangel L, Ferrero JM, Phillips M, Conibear J, Cortes J, Foxley A, de Bruin EC, McEwen R, Stetson D, Dougherty B, Sarker SJ, Prendergast A, McLaughlin-Callan M, Burgess M, Lawrence C, Cartwright H, Mousa K, Turner NC. J Clin Oncol. 2020 Feb 10;38(5):423-433

http://pubmed.ncbi.nlm.nih.gov/31841354/

Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ. Lancet Oncol. 2020 Mar;21(3):345-357

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30817-4/fulltext

Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K, Rauchhaus P, Littleford R, Cheung SYA, Cullberg M, de Bruin EC, Koulai L, Lindemann JPO, Pass M, Rugman P, Schiavon G, Deb R, Finlay P, Foxley A, Gee JMW. Clin Cancer Res. 2020 Apr 1;26(7):1574-1585

http://pubmed.ncbi.nlm.nih.gov/31836609/

Smyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, Biganzoli L, Ambrose HJ, Ashton J, Barnicle A, Cashell DD, Corcoran C, de Bruin EC, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Pass M, Rowlands V, Schiavon G, Banerji U, Scaltriti M, Taylor BS, Chandarlapaty S, Baselga J, Hyman DM. Clin Cancer Res. 2020 Apr 20:clincanres.3953

http://pubmed.ncbi.nlm.nih.gov/32312891/

Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM. Clin Cancer Res. 2018 May 1;24(9):2050-2059

http://pubmed.ncbi.nlm.nih.gov/29066505/

Dean E, Banerji U, Schellens JHM, Krebs MG, Jimenez B, van Brummelen E, Bailey C, Casson E, Cripps D, Cullberg M, Evans S, Foxley A, Lindemann J, Rugman P, Taylor N, Turner G, Yates J, Lawrence P. Cancer Chemother Pharmacol. 2018 May;81(5):873-883

http://pubmed.ncbi.nlm.nih.gov/29541803/

Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS. J Clin Oncol. 2017 Jul 10;35(20):2251-2259

http://pubmed.ncbi.nlm.nih.gov/28489509/

Featured publications

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.

Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.

AKT Inhibition in Solid Tumors With AKT1 Mutations.